Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARIS-BIO
2025-520639-17-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide in prostate adenocarcinoma, sponsored by Karolinska University Hospital. Planned start Jun 2025; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2025-520639-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520639-17-00.